• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President Laboratory Solutions Walker Corey was granted 162,866 shares, increasing direct ownership by 229% to 234,001 units (SEC Form 4)

    5/12/25 5:35:49 PM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Walker Corey

    (Last) (First) (Middle)
    RADNOR CORPORATE CENTER, BUILDING ONE,
    SUITE 200, 100 MATSONFORD ROAD

    (Street)
    RADNOR PA 19087

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Avantor, Inc. [ AVTR ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    President Laboratory Solutions
    3. Date of Earliest Transaction (Month/Day/Year)
    05/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/09/2025 A(1) 162,866 A $0 234,001 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Reflects a grant of restricted stock units that vest on May 9, 2027.
    Remarks:
    /s/ Scott Baker, as Attorney-in-Fact 05/12/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AVTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    1/4/2024$19.50 → $26.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avantor® to Host Second Quarter 2025 Earnings Call on Friday, August 1, 2025

      RADNOR, Pa., June 27, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, and will hold a conference call on the same day at 8:00 a.m. Eastern Time to discuss the results. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A replay of the

      6/27/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Participate in the 2025 RBC Capital Markets Global Healthcare Conference

      RADNOR, Pa., May 16, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Brent Jones, Executive Vice President and Chief Financial Officer, will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20, 2025 at approximately 8:00 a.m. Eastern Time.  To view the presentation slides and to hear a live audio webcast of the session, visit Events & Presentations in the I

      5/16/25 8:30:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

      RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time.  To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience

      5/2/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avantor downgraded by Goldman with a new price target

      Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

      4/29/25 8:05:35 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by TD Cowen with a new price target

      TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

      4/28/25 8:32:10 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by Stifel with a new price target

      Stifel downgraded Avantor from Buy to Hold and set a new price target of $14.00

      4/28/25 8:31:49 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials